Coherus Oncology (CHRS) Revenue Growth (5y) (2019 - 2026)
Coherus Oncology (CHRS) Revenue Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Coherus Oncology | 194.37 Mn | 27.32 Mn | 8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.73% |
| Dec 31, 2025 | -35.06% |
| Sep 30, 2025 | -36.67% |
| Jun 30, 2025 | -40.34% |
| Mar 31, 2025 | -42.04% |
| Dec 31, 2024 | -42.58% |
| Sep 30, 2024 | -44.18% |
| Jun 30, 2024 | -34.19% |
| Mar 31, 2024 | -42.62% |
| Jun 30, 2022 | 112.14% |
| Mar 31, 2022 | 226.91% |
| Dec 31, 2021 | 144.24% |
| Sep 30, 2021 | -12.71% |
| Jun 30, 2021 | 44.18% |
| Mar 31, 2021 | 46.37% |
| Dec 31, 2020 | 61.03% |
| Sep 30, 2020 | 73.77% |
| Jun 30, 2020 | 81.62% |
| Mar 31, 2020 | 82.05% |
| Dec 31, 2019 | 80.35% |